Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30676574 | 1.00 | TDP1 (0.46) | TDP1L3MBTL1CA1CA2CA4 | |
| SCHEMBL1500161 | 0.85 | TDP2 (0.46) | TDP1L3MBTL1CA1CA2CA4 | |
| SCHEMBL447986 | 0.82 | TDP1 (0.51) | TDP1L3MBTL1CA1CA2CA4 | |
| SCHEMBL446303 | 0.80 | TDP1 (0.41) | TDP1L3MBTL1CA1CA2CA4 | |
| SCHEMBL2351057 | 0.79 | METAP1 (0.49) | CA1CA2CA4CA7CA9 | |
| SCHEMBL24292160 | 0.78 | ALDH1A1 (0.38) | L3MBTL1CA2PDE4BTDP2ALDH1A1 | |
| SCHEMBL2390689 | 0.78 | ACHE (0.46) | CA1CA2CA7CA9TDP2 | |
| SCHEMBL9948162 | 0.78 | TDP1 (0.46) | TDP1L3MBTL1CA1CA2CA4 | |
| SCHEMBL2352750 | 0.78 | F7 (0.42) | TDP2PARP1PARP10TGM2CES1 | |
| SCHEMBL9140465 | 0.78 | CA9 (0.40) | TDP1CA9TDP2PARP1S100A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663630-A1 | NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR | LG Chem, Ltd. (KR) | 2025-12-17 | — | — | EP | disclosed |
| CN-113383002-B | Mononuclear iridium complex containing three orthometalated bidentate ligands and having optically directional anisotropy | UDC爱尔兰有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| WO-2024109919-A1 | PYRIDONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 盛睿泽华医药科技（苏州）有限公司 | 2024-05-30 | — | — | WO | disclosed |
| CN-117120419-A | KLK5 bicyclic heteroaromatic inhibitors | 拜奥克里斯特制药公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20220098477-A1 | MONONUCLEAR IRIDIUM COMPLEXES CONTAINING THREE ORTHO-METALLATED BIDENTATE LIGANDS AND OPTICAL ORIENTATING ANISTROPHY | UDC IRELAND LIMITED (IE) | 2022-03-31 | — | — | US | disclosed |
| EP-3906246-A1 | MONONUCLEAR IRIDIUM COMPLEXES CONTAINING THREE ORTHO-METALLATED BIDENTATE LIGANDS AND OPTICAL ORIENTATING ANISTROPHY | Merck Patent GmbH (DE) | 2021-11-10 | — | — | EP | disclosed |
| WO-2020165064-A1 | MONONUCLEAR IRIDIUM COMPLEXES CONTAINING THREE ORTHO-METALLATED BIDENTATE LIGANDS AND OPTICAL ORIENTATING ANISTROPHY | MERCK PATENT GMBH (DE) | 2020-08-20 | — | — | WO | disclosed |
| EP-2003132-A1 | HETERO COMPOUND | Astellas Pharma Inc. (JP) | 2008-12-17 | — | — | EP | disclosed |
| EP-2003132-A1 | HETERO COMPOUND | Astellas Pharma Inc. (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| CN-101023055-A | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2007-08-22 | — | — | CN | disclosed |
| EP-1795524-A1 | CYCLIC AMINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-06-13 | — | — | EP | disclosed |
| EP-1795524-A1 | CYCLIC AMINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-06-13 | — | — | EP | disclosed |
| EP-0647621-A1 | Aryl and heterocylic cyanoguanidine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-04-12 | — | — | EP | disclosed |
| US-5401758-A | Pyridinyl cyanoguanidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | TDP1 1477/4885L3MBTL1 3540/4885CA1 3338/4885 |
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | GRIN1, PARK7, GRIN3A | TDP1 603/4885L3MBTL1 2143/4885CA1 166/4885 |
| US-20220098477-A1 | MONONUCLEAR IRIDIUM COMPLEXES CONTAINING THREE ORTHO-METALLATED BIDENTATE LIGANDS AND OPTICAL ORIENTATING ANISTROPHY | ICOSLG, CCL11, CCR3 | TDP1 2653/4885L3MBTL1 1868/4885CA1 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.